OptimizeRx (OPRX) Common Equity: 2010-2025
Historic Common Equity for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $122.3 million.
- OptimizeRx's Common Equity rose 681.26% to $122.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.3 million, marking a year-over-year increase of 681.26%. This contributed to the annual value of $117.0 million for FY2024, which is 755.02% down from last year.
- Per OptimizeRx's latest filing, its Common Equity stood at $122.3 million for Q3 2025, which was up 681.26% from $119.3 million recorded in Q2 2025.
- OptimizeRx's 5-year Common Equity high stood at $140.8 million for Q2 2022, and its period low was $114.5 million during Q3 2024.
- Moreover, its 5-year median value for Common Equity was $122.5 million (2024), whereas its average is $123.6 million.
- As far as peak fluctuations go, OptimizeRx's Common Equity soared by 18658.96% in 2021, and later crashed by 1775.51% in 2023.
- Quarter analysis of 5 years shows OptimizeRx's Common Equity stood at $131.4 million in 2021, then dropped by 4.01% to $126.1 million in 2022, then rose by 0.35% to $126.6 million in 2023, then dropped by 7.55% to $117.0 million in 2024, then increased by 4.5% to $122.3 million in 2025.
- Its Common Equity was $122.3 million in Q3 2025, compared to $119.3 million in Q2 2025 and $116.3 million in Q1 2025.